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Abstract
Background: Tissue inflammation in inflammatory bowel diseases (IBD) is associated with a decrease in local pH.
The gene encoding G-protein-coupled receptor 65 (GPR65) has recently been reported to be a genetic risk factor
for IBD. In response to extracellular acidification, proton activation of GPR65 stimulates cAMP and Rho signalling
pathways. We aimed to analyse the clinical and functional relevance of the GPR65 associated single nucleotide
polymorphism (SNP) rs8005161.
Methods: 1138 individuals from a mixed cohort of IBD patients and healthy volunteers were genotyped for SNPs
associated with GPR65 (rs8005161, rs3742704) and galactosylceramidase (rs1805078) by Taqman SNP assays. 2300
patients from the Swiss IBD Cohort Study (SIBDC) were genotyped for rs8005161 by mass spectrometry based SNP
genotyping. IBD patients from the SIBDC carrying rs8005161 TT, CT, CC and non-IBD controls (CC) were recruited for
functional studies. Human CD14+ cells were isolated from blood samples and subjected to an extracellular acidic
pH shift, cAMP accumulation and RhoA activation were measured.
Results: In our mixed cohort, but not in SIBDC patients, the minor variant rs8005161 was significantly associated
with UC. In SIBDC patients, we observed a consistent trend in increased disease severity in patients carrying the
rs8005161-TT and rs8005161-CT alleles. No significant differences were observed in the pH associated activation of
cAMP production between IBD (TT, CT, WT/CC) and non-IBD (WT/CC) genotype carriers upon an acidic extracellular
pH shift. However, we observed significantly impaired RhoA activation after an extracellular acidic pH shift in IBD
patients, irrespective of the rs8005161 allele.
Conclusions: The T allele of rs8005161 might confer a more severe disease course in IBD patients. Human
monocytes from IBD patients showed impaired pH associated RhoA activation upon an acidic pH shift.
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Background
Inflammatory bowel disease (IBD) is characterized by
chronic inflammation of the intestinal tract. It is widely
accepted that it is a multifactorial inflammatory disease
determined by an interaction between genetic and envir-
onmental triggers. Inflammation is associated with an in-
crease in local proton concentration and lactate
production [1], with subsequent pro-inflammatory cyto-
kine production. An acidic environment may affect the
progression and resolution of inflammation [2–4]. To
maintain pH homeostasis, cells are required to sense
acidic changes in their environment and respond accord-
ingly. Recently, three G protein-coupled receptors
(GPCR), T cell death-associated gene 8 (TDAG8 also
known as GPR65), ovarian cancer G protein-coupled
receptor 1 (OGR1 also known as GPR68) and G protein
coupled receptor 4 (GPR4), have been shown to sense
extracellular protons and stimulate a variety of signalling
pathways [5–9]. Accumulating evidence indicates that
these particular proton-sensing receptors play a crucial
role in pH homeostasis [6, 8, 10–12].
Studies in IBD genetics have identified more than 240
regions in the human genome that increase the risk of
IBD [13–16]. The majority of IBD specific single nucleo-
tide polymorphisms (SNPs) confer an increased risk for
both CD and UC [14]. Some of the CD specific genes
are associated with bacterial response genes (e.g. NOD2
and autophagy), while for UC there are several specific
genes that are associated with immune response and
barrier function [17]. More than 70% of the IBD-risk loci
are shared with other immune-mediated inflammatory
diseases [14]. Genome wide association studies (GWAS)
have identified a locus within the GPR65 (TDAG8) gene
as one of the risk loci associated with CD and UC [13, 14].
GPR65 is highly expressed in spleen, thymus, lymph nodes
and peripheral blood leukocytes, suggesting an important
immune response function, which in turn plays a cru-
cial role during the pathogenesis of IBD. In response
to extracellular acidic pH, GPR65 activates the adenylyl
cyclase (AC)/cAMP/Protein Kinase A (PKA) pathway
through Gs proteins [5, 18] and the Rho signalling path-
way via G12/13 [5, 7]. Inflammatory processes in the gut
are frequently associated with a decrease in local pH,
potentially explaining the contribution of GPR65 to intes-
tinal inflammation in IBD.
Determining how genetic polymorphisms can affect
functionality is currently a major challenge [19]. In this
study, we aimed to test the hypothesis that genetic poly-
morphisms lead to an altered activity of GPR65, which
may result in a higher risk for gut inflammation and IBD.
We found that the GPR65 rs8005161 polymorphism has a
significant association with UC. Moreover, RhoA activa-
tion in human macrophages was significantly lower in
acidic conditions for IBD patients vs. non-IBD group.
Methods
Study subjects
The study population for the Taqman SNP assay included
591 healthy subjects and 547 IBD patients [20, 21]. All
subjects provided written informed consent to be included
in the study.
A second cohort was obtained from the Swiss Inflam-
matory Bowel Disease Cohort Study (SIBDCS), which in-
cludes patients with IBD from all regions of Switzerland
since 2006 [22]. The cohort goals and methodology are
described elsewhere [22]. We included 2300 adult IBD
patients that were enrolled in the study and previously
genotyped for the risk variant rs8005161 within the
GPR65/GALC gene locus. Genotyping was performed as
part of an analysis of the whole Swiss IBD cohort for all
SNPs that were known to be associated with IBD at that
point in time [14]. Patients with IBD were recruited at the
centres participating in SIBDCS [22]. Genotyping of
SIBDCS patients was performed using MALDI-TOFF
mass spectrometry based SNP genotyping [23].
Eight SIBDC patients carrying rs8005161-CC, 9 SIBDC
patients carrying rs8005161-CT and 9 SIBDC patients car-
rying rs8005161-TT provided blood samples for cAMP
and RhoA assays. Demographic and clinical data were
obtained at the time of the blood collection. Ten healthy
volunteers were recruited as controls. All controls were
rs8005161-CC. One individual in the control group used
nonsteroidal anti-inflammatory drugs (NSAIDs) in low
dosage on a regular basis. For this individual, cAMP
values were in the medium range of the healthy volunteers
and RhoA values could not be determined due to low cell
numbers.
Isolation of CD14+ human peripheral blood monocytes
Human peripheral blood mononuclear cells (PBMCs) were
isolated by density gradient centrifugation (Ficoll Histopa-
que 10,771 SIGMA, USA) and cryopreserved in foetal calf
serum (FCS, Gibco, Thermo Fisher Scientific) supple-
mented with 10% dimethyl sulfoxide. Upon thawing, cell
purification was then performed using EasySep™ Human
Monocyte CD14 Enrichment Kit (17,858, Stemcell, Canada)
according to the manufacturer’s instructions. Monocytes
purity was > 85% as assessed by allophycocyanin (APC)-la-
belled anti-CD14 (#17–0149-42, eBioscience, USA) and Pa-
cific Blue (PB)-labelled anti-CD45 (#304022, Biolegend,
USA) by flow cytometry (Additional file 1: Figure S1).
Genomic DNA extraction
Genomic DNA was isolated from EDTA-blood or intes-
tinal biopsies using the QIAamp DNA Mini Kit (QIA-
GEN, Hombrechtikon, Switzerland), or QIAzol (Qiagen),
respectively, according to manufacturer’s instructions.
The concentrations of genomic DNA were quantified
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using a NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies, Germany).
Genotyping
Genotyping of SNPs was performed using TaqMan allelic
discrimination assays (TaqMan SNP Genotyping Assays
C_1928636_10, C_1928640_1_ and C_11667238_10 for
the SNPs rs8005161, rs3742704 and rs1805078, respect-
ively, all from Applied Biosystems, Thermo Fisher Scien-
tific, USA) on a 7900HT Fast Real-Time PCR instrument
(Applied Biosystems, Rotkreuz, Switzerland) using the
following cycling conditions: 10min at 95 °C, 45 cycles of
95 °C for 15 s, and 60 °C for 1 min. Ten nanograms of each
genomic DNA was used per PCR reaction in a
volume of 5 μl.
The presence of either major or minor alleles of each
subject participating in the cAMP and RhoA functional
GPR65 assays was confirmed by Taqman genotyping
(rs8005161, C_1928636_10 TaqMan SNP Genotyping
Assay).
pH experiments
Monocytes were subjected to an extracellular acidic shift
from pH 7.6, where pH-sensing GPR65 receptor is
minimally active or almost silent, to pH 6.6, where it is
maximally active. Cells treated at pH 7.6 served as nega-
tive controls. pH shift experiments measuring cAMP
production were carried out in Hank’s Balanced Salt So-
lution (HBSS, 14065056, Gibco) with 25 mM HEPES
(Gibco) in a 37 °C incubator without CO2. For the meas-
urement of RhoA activation, pH shift experiments were
carried out in serum free RPMI 1640 medium containing
a bicarbonate buffer, supplemented with 2 mM Gluta-
max (35050–038, Gibco) and 25mM HEPES. The pH of
all solutions was adjusted using a calibrated pH meter
(Metrohm, Herisau, Switzerland) by the addition of ap-
propriate quantities of NaOH or HCl. Because the pH
adjusted RPMI medium also contains bicarbonate buffer,
we allowed the media to equilibrate in a 5% CO2 incuba-
tor for at least 36 h before use. Control experiments
confirmed that the media pH was stable for at least one
month under these conditions. The pH was checked
before each experiment and found to be stable within a
very narrow range (+/− 0.03). RhoA activity assays were
incubated in a 5% CO2 humidified 37 °C incubator. All
data presented in this paper are referenced to pH
measured at room temperature.
cAMP determination
cAMP accumulation following the activation of GPR65
by acidic pH was measured by a competitive cell-based
sandwich immunoassay and quantified by homogenous
time-resolved fluorescence (HTRF) technology (cAMP
Dynamic 62AM4PEC, CisBio, France). Human CD14+
monocytes were seeded at non-activating pH 7.6 HBSS
supplemented with 25mM HEPES in 384-well plates
(Cat. No. 781080, Greiner) at 10,000 cells/well in HBSS
at pH 7.6 with or without the GPR65 antagonist (10uM)
(provided by Novartis Institutes for Biomedical Research,
Switzerland), and incubated for 15 min, followed by a 30
min pH shift, which was achieved by addition of the
appropriate amount of HBSS buffer to obtain the desired
final pH (pH 7.6 or pH 6.5). All incubations were carried
out in a non-CO2 incubator at 37 °C. The optimal
activating pH for GPR65/cAMP –mediated signalling
was determined in extensive pH dose response experi-
ments (Additional file 2: Figure S2), and described in
detail in the following section. Phosphodiesterase inhibi-
tors (1 mM IBMX, 10 μM Rolipram, 1 μM BAY) were
used in all conditions. Samples and the cAMP standards
were analysed using a sigmoidal dose response model
with variable slope in using the software package Graph-
Pad Prism, La Jolla California USA, www.graphpad.com
(San Diego, CA, USA).
cAMP activation assay validation
Proton-activated GPR65/cAMP –mediated signalling
was tested using the human monocytic cell line THP-1
and CD14+ primary human monocytes isolated from
non-IBD subjects (WT/CC genotype). To confirm that
pH was associated with GPR65/cAMP –mediated signal-
ling, pH dose response experiments were performed.
Cells were starved at pH 7.6 for 2 h and subsequently
subjected to a pH shift for 10 min (pH 6.2 to 7.8 with 0.2
increments). The highest cAMP accumulation was ob-
served at pH 6.4–6.8, whereas only low cAMP concen-
trations were observed at pH 7.6–7.8 (Additional file 2:
Figure S2). Maximum activation and inactivation of
GPR65 were achieved at pH 6.5 and pH 7.6, respectively.
RhoA GTPase activation assay
Human CD14+ cells were plated in RPMI plus 10% FCS
and incubated for 1 h, followed by 2 h of starvation at
pH 7.6 in serum free RPMI. The pH shift was performed
for 10 min at pH 6.6, with the negative control (pH 7.6).
All incubations were carried out in a 5% CO2 humidified
37 °C incubator. The pH range was established in pH
dose response experiments (Additional file 3: Figure S3).
15 μg of protein was loaded per well and GTP-bound
RhoA protein levels were measured in duplicates accord-
ing to the manufacturer’s instructions (# BK124, Cyto-
skeleton, USA). Final absorbance (OD490) was measured
in a Synergy 2 micro-plate reader (Biotek, Luzern,
Switzerland). No internal standard for RhoA has been
established, therefore baseline values for RhoA cannot
be compared between experiments and only normalized
values are presented.
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RhoA activation assay validation
To confirm that RhoA activation is proton dependent,
THP-1 cells and CD14+ monocytes were subjected to a
pH shift (10 min) at different pH levels, with a prelimin-
ary starvation step (2 h) at non-activating pH (pH 7.6).
As shown in Additional file 3: Figure S3, pH 6.6 elicited
a significant increase in RhoA activation compared to
pH 6.2, 7.4 and 7.6, which, in contrast, induced no sig-
nificant activation in CD14+ monocytes and THP-1
cells. Since GPR65/G12/13/RhoA signalling was highest
at pH 6.6, this pH was used in all RhoA activity assays.
Normalization of RhoA and cAMP levels in IBD patients
and controls
cAMP and RhoA activity was measured at pH 6.5 and
6.6, respectively and all levels were normalized to RhoA
and cAMP levels from the same participant tested at
conditions with lowest RhoA and cAMP production.
This residual activity (at non-activating pH and in the
presence of the inhibitor) is unlikely to be due to
GPR65. For cAMP, we normalized to levels at pH 7.6 in
the presence of a GPR65 inhibitor. For RhoA activity we
normalized to levels at pH 7.6. Due to a high demand of
cells from human patients for the RhoA assay, the con-
trol at pH 7.6 with the GPR65 inhibitor was not feasible.
Statistical analysis
Clinical data were retrieved from the data centre of the
SIBDCS at the Lausanne University Hospital. These data
were entered into a database (Access 2000; Microsoft
Switzerland Ltd., Liab., Co., Wallisellen, Switzerland).
The Statistical Package for the Social Sciences (version
21; SPSS, Chicago, Ill., USA), GraphPad Prism, version
7, or Stata software (StataCorp., 2015. Stata Statistical
Software: Release 14. College Station, TX, USA) was
used for the statistical analysis.
The Chi-square test or Fisher’s exact test were used to
determine associations between individual SNPs and
subject phenotypes. Groups of data were compared
using Kruskal-Wallis test, Fisher’s exact, student t test or
one-way ANOVA. Data are presented as mean and inter-
quartile range (IQR). Probabilities (p, two tailed) of p <
0.05 were considered statistically significant. Throughout
this manuscript, asterisks denote significant differences
at *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
Results
Genotyping for rs8005161, rs3742704 and rs1805078 in
IBD vs. non-IBD patients by Taqman SNP assays
Genomic DNA from a group of 547 patients with IBD
(mean age 55.7 years, range 20–81) and 591 non-IBD
subjects (mean age 42.6 years, range 16–82) was used to
genotype individuals for genetic variants rs8005161 [13,
14], rs3742704 [12, 13] (both assigned to the GPR65
gene), and an additional neighbouring SNP rs1805078
(galactosylceramidase, GALC). Frequencies of homozy-
gous and heterozygous carriers of the major and minor
alleles, respectively are provided in Table 1. For
rs8005161 (GPR65), the frequency of individuals homo-
zygous for the minor T allele was significantly higher in
UC individuals compared to individuals without IBD (p
< 0.05). When comparing the number of individuals car-
rying at least one T allele (i.e. CT + TT vs. CC) we no-
ticed a trend for higher frequency of the T carriers in
UC patients which did not reach significance. In con-
trast, in individuals with CD the frequency of rs8005161
alleles did not differ from non-IBD carriers. There were
no significant differences in the genotype and allele fre-
quencies distribution between the groups for the GPR65
variant rs3742704 and the GALC variant rs1805078. In a
complementary analysis, we compared the total number
of rs8005161 minor alleles which differed significantly
between UC patients and healthy volunteers but not
when CD patients or the other SNPs were evaluated
(Additional file 4: Table S1).
When patients with UC and CD were compared, no
difference between individuals carrying at least one T
allele (i.e. CT + TT vs. CC) or number of T alleles was
found (p = 0.52; p = 0.25).
Genotyping of Swiss IBD cohort study (SIBDC) patients for
GPR65 IBD risk SNP rs8005161
The SIBDC comprises a data base of clinical and genetic
data of patients with IBD. Genotype data for rs8005161
(GPR65) for 2300 SIBDCS patients are available;
rs3742704 (GPR65) and rs1805078 (GALC) have not been
genotyped in SIBDC. No control cohort is available for
SIBDC. For the SNP rs8005161 (major allele: C, minor
allele: T), 28/2300 patients (1.2%) were homozygous TT
carriers, 430/2300 (18.7%) heterozygous CT carriers, and
1842/2300 (80.1%) were wildtype (WT) CC patients.
Allele frequencies for T and C genotype were 10.6% (426)
and 89.4% (3710), respectively (Table 2). Overall, carriers
of the T allele tended to be diagnosed more often with CD
(NS). Thus, the possible association of the T allele of
rs8005161 with UC in our initial cohort could not be con-
firmed with SIBDC data.
Interestingly, we noted a consistent trend for a
more severe disease course with an earlier age at
diagnosis (NS), a lower body mass index (p = 0.02), a
higher frequency of surgery (NS) and a higher fre-
quency of therapy with biologics (p = 0.02). A similar
trend for body mass index (BMI) and past or current
therapy with biologics was confirmed when the CC,
CT and TT genotypes were considered separately
(Additional file 5: Table S2). However, for intestinal
surgery this trend was not confirmed, and likely due
to the small size of the TT group.
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pH-dependent activation of cAMP production is not
affected by the rs8005161 T-variant in CD14+ cells
Next, we sought to determine whether the GPR65 SNP
variant rs8005161 has an impact on GPR65 protein func-
tionality and downstream signalling cascades in vitro, by
measuring production of cAMP and activation of RhoA,
two well-established second massagers downstream of
GPR65. To validate pH-dependent GPR65 activation, we
performed pH dose response experiments in a human
monocyte cell line (THP-1) and in CD14+ human mono-
cytes, isolated from healthy volunteers (Additional file 1:
Figure S1). Our data confirm maximum of cAMP and
RhoA activity at pH 6.5 and 6.6, respectively (Additional
file 2: Figure S2 and Additional file 3: Figure S3). For
subsequent experiments, these pH values were used and
normalized to levels from the same participant at condi-
tions with the least activity.
We recruited patients from the SIBDC with TT, CT
and CC genotype based on the results from SIBDCS se-
quencing, in addition to healthy CC volunteers, as de-
scribed in the Materials and Methods section. Patient
characteristics are shown in Table 3. Patients with differ-
ent alleles of rs8005161 were of similar age and had a
similar distribution of UC and CD; however, in our sam-
ple cohort, individuals with the TT genotype had lower
disease activity with a lower frequency of TNF-inhibitor
or Vedolizumab usage.
As shown in Fig. 1, normalized cAMP level increased in
PBMCs from all groups upon an extracellular acidic pH
shift from pH 7.6 to pH 6.5. In the presence of the GPR65
antagonist, no activation of cAMP production was
observed upon pH shift, confirming that pH-stimulated
cAMP production is mediated by GPR65. No difference
between individuals with CC, CT and TT genotype could
be detected (p > 0.05, data not shown), indicating that the
genotype variant of GPR65 rs8995161 has no influence on
the GPR65/Gs/cAMP pathway in human monocytes
under the conditions tested.
We also note differences in the residual cAMP activity
in the presence of the GPR65 inhibitor (Additional file 6:
Figure S4). Since these differences were observed in the
presence of the GPR65 inhibitor at the non-activating
pH 7.6, they are unlikely to represent GPR65 activity and
the underlying physiology remains unclear.
pH dependent activation of rho a production is
significantly decreased in IBD patients
The GPR65 receptor is also coupled to G12/13 proteins,
which are known to mediate small GTPase RhoA activa-
tion by phosphorylation. Consequently, we next investi-
gated the effects of the GPR65 rs8005161 variant on this
signalling pathway. An acidic pH shift from pH 7.6 to
pH 6.6 resulted in activation of RhoA. Interestingly, this
stimulation was lower for IBD patients compared to the
Table 1 Genotype frequencies and genotype association analysis of mixed population of IBD patients and healthy subjects
Minor allele homozygous carriers Minor allele carriers
rs8005161, GPR65
CC (%) CT (%) TT (%) p-value OR (CI) p-value OR (CI) Χ2(HWE) p-value
non-IBD 422 (80.8%) 95 (18.2%) 5 (1.0%)
IBD 277 (76.5%) 78 (21.6%) 7 (1.9%) 0.25 2.04 (0.64–6.5) 0.13 1.3 (0.93–1.8) 0.2
UC 105 (74.5%) 31 (21.9%) 5 (3.6%) 0.04 3.8 (1.09–13) 0.1 1.45 (0.93–2.2) 0.04
CD 172 (77.8%) 47 (21.3%) 2 (0.9%) 1 0.94 (0.18–4.9) 0.37 1.2 (0.82–1.8) 0.62
rs3742704, GPR65
AA (%) AC (%) CC (%) p-value OR (CI) p-value OR (CI) Χ2(HWE)p-value
non-IBD 317 (84.3%) 57 (15.2%) 2 (0.5%)
IBD 343 (80.3%) 78 (18.3%) 6 (1.4%) 0.29 2.7 (0.53–13) 0.17 1.3 (0.91–1.9) 0.21
UC 99 (81.1%) 23 (18.9%) 0 1 0.61 (0.03–13) 0.4 1.3 (0.73–2.1) 0.46
CD 239 (80.2%) 54 (18.1%) 5 (1.7%) 0.25 3.2 (0.61–17) 0.18 1.3 (0.89–2) 0.19
rs1805078, GALC
GG (%) GA (%) AA (%) p-value OR (CI) p-value OR (CI) Χ2(HWE) p-value
non-IBD 270 (88.2%) 33 (10.8%) 3 (1%)
IBD 363 (88.1%) 47 (11.4%) 2 (0.5%) 1 0.49 (0.082–3) 1 1.01 (0.64–1.6) 0.71
UC 116 (86.6%) 15 (11.2%) 3 (2.2%) 0.37 2.3 (0.46–11.6) 0.63 1.6 (0.63–2.1) 0.570
CD 242 (88.6%) 31 (11.4%) 0 0.25 0.16 (0.008–3.1) 0.9 0.96 (0.58–1.6) 1
Odds ratio (OR) with 95% confidence interval (CI) and p–value for WT vs. homozygous and heterozygous allele carriers is indicated. Statistical analysis: Fisher’s
exact test with two-tailed values; HWE – calculated χ2 for Hardy-Weinberg Equilibrium. CD: Crohn’s disease, GALC: galactosylceramidase, GPR65: G protein-coupled
receptor 65 (also known as TDAG8), IBD: inflammatory bowel disease, UC: ulcerative colitis
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Table 3 Demographic and clinical data of healthy volunteers and patients with different alleles of GPR65 SNP rs8005161 used for
further analysis
Healthy controls rs8005161 CC rs8005161 CT rs8005161 TT
Number of patients 8 8 9 9
Gender, females 3 (37.5%) 4 (50%) 3 (33%) 6 (66%)
Age (median ± IQR) 42 (37.5–47.5) 46.7 (37.9–50.6) 41.3 (33.9–51.4) 43.1 (27.5–48.8)
Diagnosis
UC/ CD (percent UC) NA 4/4 (50%) 6/3 (66%) 6/3 (66%)
Disease severity
Harvey-Bradshaw Index (median, IQR) NA 6.0 (4.3–7.5) 4 (3–4) 1 (0.5–1)
UC Severity Index (median, IQR) NA 4.0 (3.3–4.8) 7.5 (3.5–10) 0 (0–1.5)
Medical history
Azathioprine / 6-Mercaptopurine NA 1/8 1/9 2/8
Methotrexate NA 0/8 1/9 0/8
Tacrolimus NA 1/8 0/9 0/8
Tumor necrosis factor inhibitor NA 4/8 3/9 1/8
Vedolizumab NA 4/8 5/9 1/8
Systemic steroids ≥10mg/d NA 0/8 3/9 1/8
Oral mesalazine/ sulfasalazine NA 5/8 3/9 4/8
CD Crohn’s disease, IBD inflammatory bowel disease, IQR interquartile range, NA not applicable, UC ulcerative colitis
Table 2 Demographic characteristics and biological phenotypes of carriers of various alles of the GPR65 SNP rs8005161 for patients
from the SIBDC
rs8005161 CC rs8005161 CT or TT p-value (Fisher or Kruskal-Wallis)
Diagnosis
Crohn’s disease 1051 (57.1%) 284 (62.0%) 0.057 (NS)
UC / IC 791 (42.9%) 174 (38.0%)
Gender 953 (51.7%) 238 (52.3%) 0.83 (NS)
889 (48.3%) 220 (47.7%)
Age at diagnosis [years]
median, (IQR), 26.4, (19.1–36.6), 25.1, (18.2–36.3), 0.059 (NS)
min – max 0.5–81.4 2.6–77.5
Disease duration [years]
Median (IQR), 12.2, (7.3–20.5), 12.3, (7.3–20.7), 0.998 (NS)
min – max 0.1–52.4 0.3–56.6
Last BMI [kg /m2]
median, (IQR), 23.8, (21.1–26.7), 23.2, (20.7–26.1), 0.020
min – max 12.6–47.1 13.2–46.3
Intestinal surgery
No (n = 1620) 1311 (71.2%) 309 (67.5%) 0.123 (NS)
Yes (n = 680) 531 (28.8%) 149 (32.5%)
Past or current therapy with biologics
No (n = 1107) 909 (49.3%) 198 (43.2%) 0.021
Yes (n = 1193) 933 (50.7%) 260 (56.8%)
Significant phenotypes are indicated in bold
IQR interquartile range, IC indeterminate colitis, CD Crohn’s disease, UC ulcerative colitis
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healthy control subjects (p < 0.05, Fig. 2a). No differential
RhoA GTPase activation in CD14+ monocytes according
to the rs8005161 genotype could be detected (Fig. 2b).
Experiments with the GPR65 antagonist were not feas-
ible due to the limited amount of human material. Thus,
CD14+ monocytes from IBD patients demonstrate
reduced RhoA activation upon acidic pH shift compared
to healthy control subjects.
Discussion
In this study, we addressed the clinical relevance of the
SNP rs8005161 GPR65 variant as a risk gene for IBD,
and tested a potential functional consequence of this
SNP variant in human CD14+ monocytes/ macrophages.
We found several indications for a more severe clinical
phenotype in IBD patients with the T allele of the GPR65
SNP rs8005161 in patients from the SIBDC. We examined
proton-activated TDAG8 -mediated signalling pathways in
CD14+ monocytes from IBD rs8005161 (WT/CC, CT, TT)
and non-IBD (WT/CC) carriers. We observed lower RhoA
GTPase activation upon an acidic pH shift in IBD patients
compared to healthy volunteers. No differential activation
of either RhoA or cAMP stimulated by acidosis was
detected in individuals with different rs8005161 genotypes,
thus rendering major effects of the CC, CT or TT
variants on cAMP or RhoA activation under the con-
ditions tested unlikely.
The GPR65 gene encodes a transmembrane receptor,
which is reported to function as a proton sensor [5, 18, 24,
25]. Previously, psychosine (1-β-D-galactosylsphingosine)
Fig. 1 Formation of cAMP in human CD14+ monocytes upon pH shift from pH 7.6 to pH 6.5. 10 μM of G protein-coupled receptor 65 (GPR65)
antagonist was used when indicated (+). Human CD14+ cells were obtained from IBD patients carrying either rs8005161 TT, CT or WT/CC
genotype, and non-IBD and WT/CC genotype. Produced cAMP was calculated as a ratio of the respective condition relative to pH 7.6 plus
inhibitor. No significant differences between the genotypes were identified. cAMP: cyclic adenosine monophosphate, IBD: inflammatory bowel
disease, WT: Wild type
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Fig. 2 Formation of RhoA in human CD14+ monocytes upon pH shift from pH 7.6 to pH 6.6. a Activated GTPase RhoA in human CD14+
monocytes upon pH shift from pH 7.6 to pH 6.6 (n = 6). Carriers of rare TT genotype showed the lowest level of RhoA activation compared to
heterozygous CT, WT/CC or healthy WT/CC subjects. b Significantly decreased activation of GTPase RhoA in CD14+ monocytes of IBD (WT/CC, CT,
TT) patients compared to non-IBD (WT/CC) genotype carriers upon pH shift 7.6 to 6.6. Data points are normalized to pH 7.6 condition (n = 6 non-
IBD, n = 18 IBD). Each dot represents a single patient, one-way ANOVA, t-test, * p < 0.05. No significant differences between carriers of different
alleles were identified. IBD: inflammatory bowel disease, WT: Wild type
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was proposed to activate GPR65 [26], however the study
showed no data for the specific interaction of psychosine
with GPR65, and subsequent reports have not supported
this finding [5, 18, 24, 25]. Recently, BTB09089
(3-[(2,4-dichlorobenzyl)thio]-1,6-dimethyl-5,6-dihydro-1H--
pyridazino[4,5 e][1,3,4]thiadiazin-5-one) has been reported
to be an allosteric modulator for GPR65 [27]. However,
despite numerous studies, the physiological role of GPR65
under inflammatory conditions (acidic pH) is unclear.
GPR65 is mainly expressed in immune cells [28, 29], sug-
gesting an immunological role. Proton activation of GPR65
stimulates second messengers Gs/cAMP and G12/13/RhoA
[5, 7, 30]. Second messenger cAMP is produced by the acti-
vation of adenylyl cyclase, which converts adenosine tri-
phosphate (ATP) into the biologically active signalling
mediator, with subsequent degradation by phosphodiester-
ases (PDEs). The role of cAMP in regulating inflammatory
diseases has been well studied [31, 32] and there is contin-
ued interest in cAMP as a therapeutic target to treat in-
flammatory diseases [33]. Increased cAMP levels can
inhibit the secretion of proinflammatory cytokines and che-
mokines [27, 30, 34–37], inhibit inflammatory cell migra-
tion [38–40] and modulate epithelial barrier formation
[41–43]. In the present study, we observed TDAG8–medi-
ated increases in cAMP at reduced pH in peripheral mono-
cytes. We could confirm TDAG8 signalling by using a
specific TDAG8 inhibitor. However, no differences between
IBD variants and non-IBD subjects were detected, suggest-
ing that major effects of cAMP signalling at the conditions
tested unlikely.
There is increasing interest in small GTPases of the Rho
family as candidates for therapeutic intervention due to
their involvement in a wide variety of diseases. Rho func-
tions as a molecular switch, in the GTP-bound conform-
ation, the proteins are able to interact with their
downstream targets and transmit signals to the cell [44].
Rho GTPases are critical regulators of many cellular func-
tions including cytoskeletal remodelling, cell-cell adhesion,
cell polarization, vesicle trafficking, morphogenesis, apop-
tosis, cell migration, organelle development, membrane
transport pathways and tumour motility and proliferation
[44–51]. Our study identified a lower RhoA activation in
response to acidic pH from monocytes of IBD patients
compared to healthy volunteers, but no differences between
the rs8005161 GPR65 CC, CT or TT variants. These data
are in line with a role of pH sensing for immune activation
in IBD pathogenesis. The reasons for this differential activa-
tion remain unclear and possible explanations include a
higher baseline activation in IBD patients with (subclinical)
disease. Alternatively, cell migration and wound healing
may be impaired in IBD patients. Thus, future studies
should address this issue with more mechanistic studies.
Our analysis did not identify genotype dependent
changes in either RhoA or cAMP activation. There
might be several explanations for these findings: i) differ-
ential activation might only be relevant in subsets of
macrophages or other cell types. ii) differential effects of
the genotypes might not be mediated via cAMP or RhoA
but other properties of GPR65. One example would be
genotype dependent differential inhibition of Rac1.
Inhibition of Rac1 via the via G12/13 pathway has as
described previously [52] and Rac1 inhibition has been
associated with remission in IBD [53]. iii) finally, consid-
ering small effects of rs8005161 polymorphisms [14] (in-
crease of CD risk by an odds ratio (OR) of 1.16 (1.09–
1.22) and UC by an OR of 1.14 (1.08–1.21)) our study
with a limited number of participants might be under-
powered to detect small differences in the activation of
secondary messengers.
Most IBD risk genes increase the risk of both, UC and
CD in carriers [14]. In a recent meta-analysis, OR for
carriers of rs8005161 for CD was 1.156 (CI: 1.092–
1.222), the OR for UC was 1.143 (CI: 1.076–1.213) [14].
In agreement with a general increase in the risk for IBD,
no differences between allelic frequencies of rs8005161
between CD and UC patients was found in our study.
Associations of IBD genotypes with subsequent disease
course have been difficult to establish. However, disease
location in CD (ileal vs. colonic) could be predicted by a
compound genetic risk score [54]. As expected, for
rs8005161 no association with disease location was
observed in agreement with highly similar OR for CD
(predicting ileal disease) and UC (predicting colonic dis-
ease). Furthermore, genetic predisposition can predict
onset of disease and individuals with a high genetic bur-
den developed CD 5 years earlier than individuals with
the lowest genetic risk [55]. In agreement with this no-
tion, carriers of the rs8005161 T allele developed disease
1.3 years before rs8005161-CC carriers; however, prob-
ably due to the wide distribution of the year of onset of
disease, this difference failed to reach statistical signifi-
cance. Associations of genetic risks and clinical course
or treatment of IBD are insufficiently understood; most
likely due to limited precision of data recorded in large
IBD cohort data bases. Analysis of the SIBDC data evi-
denced an association of need for more intense treat-
ment, i.e. biological therapy (p = 0.02) and a trend for
more intestinal surgery (p = 0.13) in our patient cohort.
However, even nominally significant associations would
not remain significant after Bonferroni correction, point-
ing to the need of large, well-characterized cohorts for
studying the important questions of IBD genetic risk
and disease course and treatment.
Our study has various strengths and limitations. We were
able to use a large prospective cohort of well-characterized
IBD patients to test associations of rs8005161 genotypes
with disease course. Moreover, we were able to recruit
patients with IBD and rare genotypes, thus enabling
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functional studies with individuals of each genotype for
RhoA and cAMP activation. Limitations include the small
sample size for all experiments, and lack of non-wildtype
carriers of rs8005161 in the control population. Limited
amount of patient material prohibited inclusion of the
GPR65 inhibitor for RhoA tests. Future studies should
also address expression levels of GPR65 RNA and start
gene sequencing to test for polymorphisms associated
with specific variants of the SNP.
Conclusions
In summary, in the SIBDC patients, there is a trend
for a more severe disease course for T allele carriers
and a tendency towards a lower probability for
anti-TNF treatment. In addition, we confirmed a sig-
nificant association between the rare homozygote
rs8005161 TT genotype and a diagnosis of UC. Our
study did not identify biochemical changes in individ-
uals with various genotypes of rs8005161, however we
identified a lower activation of RhoA upon an acidic
pH shift in IBD patients. Thus, pH sensors may be
interesting new targets for pharmacological interven-
tion in intestinal inflammation.
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